MedTrace Logo

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00589550 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-06-08

Study results available
· View outcomes & findings →

Summary

RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with sorafenib may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

PEG-interferon alfa-2b

administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.

DRUG

Sorafenib

GENETIC

gene expression analysis

GENETIC

polymerase chain reaction

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

flow cytometry

OTHER

immunoenzyme technique

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Thomas Olencki

    lead OTHER

Principal Investigators

  • Thomas E. Olencki, DO · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00589550 on ClinicalTrials.gov